Abstract:Background: Myeloid-derived suppressor cells (MDSCs) are the major factor in gastric cancer (GC) immune evasion. Nevertheless, the molecular process underlying the expansion of MDSCs induced by tumor-derived exosomes (TDEs) remains elusive. Methods: The levels of exosomal and soluble PD-L1 in ninety GC patients were examined via enzyme-linked immunosorbent assay (ELISA) to determine their prognostic value. To investigate the correlation between exosomal PD-L1 and MDSCs, the percentage of MDSCs in the peripheral blood of 57 GC patients was assessed via flow cytometry. Through ultracentrifugation, the exosomes were separated from the GC cell supernatant and detected via Western blotting, nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM). The function of exosomal PD-L1 in MDSCs was evaluated via immunofluorescence, Western blotting and flow cytometry in a GC cell-derived xenograft (CDX) model. Results: The overall survival (OS) of GC patients in the high exosomal PD-L1 group was significantly lower than that of patients in the low exosomal PD-L1 group (P = 0.0042); however, there was no significant correlation between soluble PD-L1 and OS in GC patients (P = 0.0501). Furthermore, we found that the expression of exosomal PD-L1 was positively correlated with the proportions of polymorphonuclear MDSCs (PMN-MDSCs, r = 0.4944, P < 0.001) and monocytic MDSCs (M-MDSCs, r = 0.3663, P = 0.005) in GC patients, indicating that exosomal PD-L1 might induce immune suppression by promoting the aggregation of MDSCs. In addition, we found that exosomal PD-L1 might stimulate MDSC proliferation by triggering the IL-6/STAT3 signaling pathway in vitro. The CDX model confirmed that exosomal PD-L1 could stimulate tumor development and MDSC amplification. Conclusions: Exosomal PD-L1 has the potential to become a prognostic and diagnostic biomarker for GC patients. Mechanistically, MDSCs can be activated by exosomal PD-L1 through IL-6/STAT3 signaling and provide a new strategy against GC through the use of exosomal PD-L1 as a treatment target.

Downregulation of CD40 Expression Contributes to the Accumulation of Myeloid-Derived Suppressor Cells in Gastric Tumors.

CD40 Controls CXCR5-induced Recruitment of Myeloid-Derived Suppressor Cells to Gastric Cancer.

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

IFN-γ producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment

[The Number of Myeloid-Derived Suppressor Cells in the Peripheral Blood and Tumor Tissues in Patients with Gastric Cancer and Its Clinical Significance].

Increased Circulating GrMyeloid-derived Suppressor Cells Correlated with Tumor Burden and Survival in Locally Advanced Cervical Cancer Patient

CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer

PMN-MDSCs Accumulation Induced by CXCL1 Promotes CD8+ T Cells Exhaustion in Gastric Cancer.

Tumor-induced Myeloid-Derived Suppressor Cells Promote Tumor Progression Through Oxidative Metabolism in Human Colorectal Cancer

Myeloid-derived suppressor cells in the tumor microenvironment reduce uncoupling protein 1 expression to boost immunosuppressive activity

Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients.

Exosomal PD-L1 induces MDSCs accumulation through IL-6/STAT3 pathway in gastric cancer

DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs Via the CXCL1-CXCR2 Axis.

Circulating And Tumor-Infiltrating Myeloid-Derived Suppressor Cells In Patients With Colorectal Carcinoma

Depletion of Regulatory T Cells Facilitates Growth of Established Tumors: A Mechanism Involving the Regulation of Myeloid-Derived Suppressor Cells by Lipoxin A4

Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC

G-CSF is a Key Modulator of MDSC and Could Be a Potential Therapeutic Target in Colitis-Associated Colorectal Cancers.

The expansion of MDSCs induced by exosomal PD-L1 promotes the progression of gastric cancer

Targeting Depletion of Myeloid-Derived Suppressor Cells Potentiates PD-L1 Blockade Efficacy in Gastric and Colon Cancers.

Transmembrane Tumor Necrosis Factor-Α Promotes the Recruitment of MDSCs to Tumor Tissue by Upregulating CXCR4 Expression Via TNFR2